Athersys Announces Adjournment of Special Meeting Date
Special Meeting to be Reconvened Thursday, February 28, 2013
CLEVELAND, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX)
announced today that it has adjourned its special meeting of stockholders
scheduled for 9:00 a.m. Eastern Time today, February 21, 2013, until 9:00 a.m.
Eastern Time on Thursday, February 28, 2013, in order to ensure a quorum
exists and to solicit additional proxies for a warrant exercise price
adjustment proposal to approve the adjustment of the exercise price of the
Company's March 2012 warrants from $2.07 per share to $1.01 per share.
The only proposal submitted for the stockholders' consideration at the special
meeting, prior to its adjournment, was the proposal to adjourn the special
meeting to a later date to allow the Company to ensure a quorum exists and to
solicit additional proxies for the warrant exercise price adjustment proposal
described above, which was approved at the special meeting.
To conduct business at the reconvened special meeting, a quorum, consisting of
at least a majority of the shares of common stock outstanding as of the record
date, will be required. As of the record date of January 23, 2013, which will
not change for the reconvened special meeting, 53,058,632 shares of common
stock were outstanding. The Company's Board of Directors has recommended that
Company stockholders vote "FOR" the proposal.
The special meeting will reconvene on Thursday, February 28, 2013, at 9:00
a.m. Eastern Time at the offices of Jones Day, 901 Lakeside Avenue, Cleveland,
Ohio 44114, City View Room. Valid proxies submitted by Company stockholders in
connection with the February 21 meeting will continue to be valid for purposes
of the reconvened special meeting.
Athersys stockholders are encouraged to read the definitive proxy statement
dated January 24, 2013, which includes a comprehensive review of the warrant
exercise price adjustment proposal.
How to Vote Your Shares
The Company urges all stockholders to vote as soon as possible:
*By Phone: Call toll-free 1-800-652-VOTE (8683) and have your control
number as listed on the voting instruction form ready and follow the
*Over the Internet: stockholders may also cast their votes on the internet
at www.investorvote.com/ATHX as long as they know their proxy control
number on their notice of internet availability or proxy card;
*Through their Stockbroker: stockholders may also contact their
stockbrokers for help with casting their votes;
*By Mail: stockholders may vote by mailing in the proxy card they received
with their definitive proxy statement; or
*In Person: stockholders may vote by attending the special meeting in
person on Thursday, February 28, 2013 at 9:00 a.m. Eastern Time at the
offices Jones Day, 901 Lakeside Avenue, Cleveland, Ohio 44114, City View
*Votes submitted by phone or over the internet must be received by 11:59
p.m. Eastern Time on February 27, 2013. Please note that voting by phone
or internet may require that you have your proxy control number available.
This number is printed on the notice of internet availability of proxy
materials or proxy card mailed to you.
The discussion in this press release of the Company's proposal to adjust the
exercise price of the March 2012 warrants is qualified in its entirety by the
description of the proposal contained in the Company's definitive proxy
statement, which was filed with the Securities and Exchange Commission (SEC)
on January 24, 2013. BEFORE VOTING, SHAREHOLDERS ARE URGED TO READ THE PROXY
STATEMENT, SPECIFICALLY INCLUDING THE DESCRIPTION OF THE WARRANT EXERCISE
PRICE ADJUSTMENT PROPOSAL CONTAINED THEREIN. The definitive proxy statement is
available free of charge at www.sec.gov. In addition, investors and
stockholders can obtain free copies of the definitive proxy statement by
contacting Athersys at Athersys, Inc., 3201 Carnegie Avenue, Cleveland, Ohio
44115-2634, Attention: Corporate Secretary, or at
Athersys is a clinical stage biotechnology company engaged in the discovery
and development of therapeutic product candidates designed to extend and
enhance the quality of human life.The Company is developing its MultiStem^®
cell therapy product, a patented, adult-derived "off-the-shelf" stem cell
product platform for disease indications in the cardiovascular, neurological,
inflammatory and immune disease areas. The Company currently has several
clinical stage programs involving MultiStem, including for treating
inflammatory bowel disease, ischemic stroke, damage caused by myocardial
infarction, and for the prevention of graft versus host disease. Athersys has
also developed a diverse portfolio that includes other technologies and
product development opportunities, and has forged strategic partnerships and
collaborations with leading pharmaceutical and biotechnology companies, as
well as world-renowned research institutions in the United States and Europe
to further develop its platform and products.
The Athersys, Inc. logo is available at
CONTACT: William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
Lisa M. Wilson
Tel: (917) 543-9932
Press spacebar to pause and continue. Press esc to stop.